# **CMS Manual System** Pub. 100-20 One-Time Notification

Department of Health & Human Services (DHHS) Centers for Medicare & Medicaid Services (CMS)

**Transmittal 106** 

Date: AUGUST 24, 2004

# CHANGE REQUEST 3419

**I. SUMMARY OF CHANGES:** This One-Time Notification informs Medicare carriers to update the payment limit for HCPCS codes J9045 (Carboplatin injection) and J9310 (Rituximab cancer treatment) effective with dates of service on or after April 1, 2004, and on or before December 31, 2004.

#### NEW/REVISED MATERIAL - EFFECTIVE DATE: April 1, 2004. \*IMPLEMENTATION DATE: September 24, 2004

Disclaimer for manual changes only: The revision date and transmittal number apply to the red italicized material only. Any other material was previously published and remains unchanged. However, if this revision contains a table of contents, you will receive the new/revised information only, and not the entire table of contents.

#### II. CHANGES IN MANUAL INSTRUCTIONS: (N/A if manual not updated.)

R/N/D	CHAPTER/SECTION/SUBSECTION/TITLE
N/A	

#### **\*III. FUNDING:**

These instructions shall be implemented within your current operating budget.

#### **IV. ATTACHMENTS:**

	<b>Business Requirements</b>
	Manual Instruction
	<b>Confidential Requirements</b>
X	<b>One-Time Notification</b>
	<b>Recurring Update Notification</b>

\*Medicare contractors only

# **Attachment – One-Time Notification**

Pub. 100-20	Transmittal: 106	Date: August 24, 2004	Change Request 3419

# **SUBJECT:** MMA Drug Pricing Update—Payment Limits for J9045 (Carboplatin injection) and J9310 (Rituximab cancer treatment)

#### I. GENERAL INFORMATION

**A. Background:** This instruction provides updated payment limits for drugs granted an exception from the 85 percent general rule used in the calculation for pricing Medicare Part B drugs for calendar year 2004 under the exceptions process described in section 303(b) (2) of Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (MMA). In particular, this instruction informs Medicare carriers to replace the MMA payment limit for J9045 (Carboplatin injection) and J9310 (Rituximab cancer treatment) with the new rates listed in this transmittal for dates of service on or after April 1, 2004 and on or before December 31, 2004.

**B.** Policy: Section 303(b)(2) of the MMA specifies that we may adjust the percentage used in the calculation for pricing Medicare Part B drugs effective January 1, 2004, based on data and information submitted by the manufacturer after October 15, 2003, and before January 1, 2004. Based on information received by CMS, the payment limit for J9045 and J9310 have been revised. From April 1, 2004, through December 31, 2004, the Medicare payment limits for the HCPCS drug codes listed below, when they are not paid on a cost or prospective payment basis, apply. The payment limit for J9045 and J9310 supercedes the payment limit published in Pub. 100-04, Change Request (CR) 3161, Transmittal 119, dated March 15, 2004 and any other publication published prior to this document. Note that the absence or presence of a HCPCS code and its associated payment limit does not indicate Medicare coverage of the drug.

				2004 Payment Limit for Drugs (other
				than ESRD drugs separately billed
			AWP	by independent ESRD Facilities and
Status	HCPCS	Short Description	%	drugs infused through DME)
OLD	J9045	Carboplatin injection	88	\$137.54
NEW	J9045	Carboplatin injection	86	\$135.15
OLD		Rituximab cancer		
	J9310	treatment	81	\$427.28
NEW		Rituximab cancer		
	J9310	treatment	83	\$438.38

**C. Provider Education:** A provider education article related to this instruction will be available at <u>www.cms.hhs.gov/medlearn/matters</u> shortly after the CR is released. You will receive notification of the article release via the established "medlearn matters" listserv. Contractors shall post this article, or a direct link to this article, on their Web site and include information about it in a listserv message within 1 week of the availability of the provider education article. In addition, the provider education article must be included in your next regularly scheduled bulletin.

#### **II. BUSINESS REQUIREMENTS**

"Shall" denotes a mandatory requirement "Should" denotes an optional requirement

Requirement Number	Requirements	Responsibility ("X" indicates the columns that apply)								
						Shared System Maintainers				Other
		FI	RHHI	Carrier	DMERC	FISS	MCS	VMS	CWF	
3419.1	Carriers shall use the specific payment limit for HCPCS drug codes J9045 and J9310 in the table under section B of this instruction. The payment limits in this instruction apply to claims with dates of service on or after April 1, 2004 and on or before December 31, 2004.			X						
3419.2	Carriers shall not search and adjust claims that have already been processed unless brought to their attention.			Х						

## III. SUPPORTING INFORMATION AND POSSIBLE DESIGN CONSIDERATIONS

#### A. Other Instructions: N/A

X-Ref Requirement #	Instructions

## B. Design Considerations: N/A

X-Ref Requirement #	<b>Recommendation for Medicare System Requirements</b>

## C. Interfaces: N/A

- D. Contractor Financial Reporting /Workload Impact: N/A
- E. Dependencies: N/A
- F. Testing Considerations: N/A

## IV. SCHEDULE, CONTACTS, AND FUNDING

Effective Date*: April 1, 2004	Medicare contractors shall
Implementation Date: September 24, 2004	implement these instructions within their current operating
	budgets.
<b>Pre-Implementation Contact(s):</b> Marjorie Baldo	-
(marjorie.baldo@cms.hhs.gov) at 410-786-4617	
<b>Post-Implementation Contact(s):</b> Appropriate	
regional office	

\*Unless otherwise specified, the effective date is the date of service.